


| | | |
|-----------|---------------|----------|
| APPROVED | O. G. FIGUOUE | |
| BY | CLASS | SUBCLASS |
| DRAFTSMAN | 444 | 1521 |

Anti- β 3



Normal Skin

FIG. 1A



Granulation Tissue

FIG. 1B


Anti- β 3

Anti- β 1



Normal Skin

FIG. 1C



Granulation Tissue

FIG. 1D

Anti- β 1

| | | |
|-----------|-----------|----------|
| APPROVED | O.G. FIG. | |
| BY | CLASS | SUBCLASS |
| DRAFTSMAN | | |

Normal Skin

Anti-vWF




FIG. 2A

Granulation Tissue

Anti-vWF





FIG. 2B

| | | |
|-----------|-----------|----------|
| APPROVED | O.G. FIG. | |
| BY | CLASS | SUBCLASS |
| DRAFTSMAN | | |


Normal Skin



Anti-laminin

FIG. 2C


Granulation Tissue



Anti-laminin


FIG. 2D

| | | |
|-----------|-----------|----------|
| APPROVED | O.G. FIG. | |
| BY | CLASS | SUBCLASS |
| DRAFTSMAN | | |



Bladder Cancer

FIG. 3A




Colon Cancer


FIG. 3B

RECEIVED
JAN 14 1988
FBI - NEW YORK

| | | |
|-----------|-----------|----------|
| APPROVED | O.G. FIG. | |
| BY | CLASS | SUBCLASS |
| DRAFTSMAN | | |



Breast Cancer
FIG. 3C



Lung Cancer
FIG. 3D

RECEIVED
JAN 11 1994
FBI - NEW YORK

| | | |
|-----------|-----------|----------|
| APPROVED | O.G. FIG. | |
| BY | CLASS | SUBCLASS |
| DRAFTSMAN | | |

FIG. 5A

Untreated
Anti- β_1




FIG. 5B

Untreated
Anti- $\alpha\beta_3$




FIG. 5C

bFGF Treated
Anti- $\alpha\beta_3$



| | | |
|-----------|------------|----------|
| APPROVED | O. G. FIG. | |
| BY | CLASS | SUBCLASS |
| DRAFTSMAN | | |




FIG. 6

03/08/2014
14:14:14
10/10/2014

| | | |
|-----------|-----------|----------|
| APPROVED | O.G. FIG. | |
| BY | CLASS | SUBCLASS |
| DRAFTSMAN | | |



FIG. 7A

FIG. 7B

FIG. 7C

| | | |
|-----------|-----------|----------|
| APPROVED | O.G. FIG. | |
| BY | CLASS | SUBCLASS |
| DRAFTSMAN | | |

FIG. 8A
Control



bFGF



FIG. 8B



FIG. 8C
Anti- β_1




FIG. 8D
Anti- $\alpha_v\beta_5$



FIG. 8E
Anti- $\alpha_v\beta_3$

| | | |
|-----------|-----------|----------|
| APPROVED | O.G. FIG. | |
| BY | CLASS | SUBCLASS |
| DRAFTSMAN | | |

FIG. 9A



Control Peptide
Tumor

FIG. 9B



Cyclic RGD
Tumor

FIG. 9C



Cyclic RGD
Adjacent CAM

CONFIDENTIAL
1977
1978

| | | |
|-----------|---------|----------|
| APPROVED | G. FIG. | |
| BY | CLASS | SUBCLASS |
| DRAFTSMAN | | |

FIG. 10C
Anti- $\alpha V\beta_3$ (LM609)



FIG. 10B
Anti- $\alpha V\beta_5$ (P3G2)



FIG. 10A
Control



| | | |
|-----------|------------|----------|
| APPROVED | O. G. FIG. | |
| BY | CLASS | SUBCLASS |
| DRAFTSMAN | | |




FIG. 12

RECEIVED
JAN 17 1978
FBI - NEW YORK